The field of solid organ transplantation has developed
enormously in the last three decades andwhat was pioneering
surgery has now become routine. Outcomes
are no longer considered in terms of 1-year survival,
but clinicians and patients are looking to 20 years
and beyond. The current success of transplantation is
based on many different factors: developments in surgical
technique, better immunosuppression, improved
anesthetic and intensive care, improved microbiology,
and close collaboration between – all those involved in
the transplant pathway have contributed....
Artificial neural networks may probably be the single most successful technology in the last two decades which has been widely used in a large variety of applications. The purpose of this book is to provide recent advances of architectures, methodologies, and applications of artificial neural networks.
However, despite sharing a common signature CLLs expressing mutated and unmutated
IgVH genes differentially express more than 100 genes. Among these, over-expression of
genes encoding zeta-chain-associated protein 70 (ZAP-70), lipoprotein lipase (LPL), BCL-7a,
dystrophin and gravin are observed in the aggressive unmutated cases, while stable
mutated cases over-express Wnt3, CTLA-4, NRIP1 nuclear receptor gene, ADAM29 and the
transcription factor TCF7 . These results suggest that indolent mutated and aggressive
unmutated CLLs constitute two variants of the same disease.
Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí hóa học quốc tế đề tài : Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/ refractory non-transplant multiple myeloma patients: a single center experience from Thailand
Health and Quality of Life Outcomes
Spanish validation of the "Kidney Transplant Questionnaire": a useful instrument for assessing health related quality of life in kidney transplant patients
Pablo Rebollo*1, Francisco Ortega†1,2, Teresa Ortega†2, Covadonga Valdés†2, Mónica García-Mendoza†1 and Ernesto Gómez†3
Address: 1Outcomes Research Unit. Nephrology Unit. Hospital Central de Asturias. C/ Celestino Villamil S/N. 33006. Oviedo. Spain, 2Institute "Reina Sofía" for Nephrological Research. Oviedo. Spain and 3Nephrology Unit.
(BQ) Part 2 book "Noyes' knee disorders surgery, rehabilitation, clinical outcomes" presents the following contents: Posterolateral ligament injuries - diagnosis, operative techniques, and clinical outcomes; meniscus transplantation; tibial and femoral osteotomy for varus and valgus knee syndromes; unicompartmental knee replacement for varus or valgus malalignment,...
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Short-term outcomes of cadaveric lung transplantation in ventilator-dependent patients...
For recipients of allogeneic hematopoietic stem cell transplantation
(HSCT), Mycobacterium tuberculosis may act as
a signi¢cant opportunistic pathogen in the early posttransplantation
period, especially in areas where tuberculosis
(TB) is endemic.
Hematopoietic Stem Cell Transplantation This is the best therapy for the young patient with a fully histocompatible sibling donor (Chap. 108). Human leukocyte antigen (HLA) typing should be ordered as soon as the diagnosis of aplastic anemia is established in a child or younger adult. In transplant candidates, transfusion of blood from family members should be avoided so as to prevent sensitization to histocompatibility antigens; while transfusions in general should be minimized, limited numbers of blood products probably do not seriously affect outcome.
Outcomes following both transplant and immunosuppression have improved with time. High doses of cyclophosphamide, without stem cell rescue, have been reported to produce durable hematologic recovery, without relapse or evolution to MDS, but this treatment can produce sustained severe fatal neutropenia and response is often delayed. New immunosuppressive drugs in clinical trial may further improve outcome.
Chronic Myelogenous Leukemia: Treatment
The therapy of CML is changing rapidly because we have a proven curative treatment (allogeneic transplantation) that has significant toxicity and a new targeted treatment (imatinib) with excellent outcome based on 5-year follow-up data. Therefore, physician experience and patient preference must be factored into the treatment selection process. Discussion of both treatment options with a patient is indicated. The decision should focus on the outcomes, risks, and toxicities of the various approaches.